Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib PK and Safety in Hepatic Impairment
NCT04831944Phase 1Completed
- Sponsor
- Incyte
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of parsaclisib in malignant neoplasms (advanced stage) (4 arms), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Parsaclisib at 5 Days, Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of Parsaclisib at 5 Days and 1 more. Started Mar 2021; status: completed.
02
Drugs
parsaclisib
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT04831944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831944.